EA201001405A1 - Стимуляторы секреции инсулина - производные пиридопиразинонов, способы их получения и их применение для лечения диабета - Google Patents

Стимуляторы секреции инсулина - производные пиридопиразинонов, способы их получения и их применение для лечения диабета

Info

Publication number
EA201001405A1
EA201001405A1 EA201001405A EA201001405A EA201001405A1 EA 201001405 A1 EA201001405 A1 EA 201001405A1 EA 201001405 A EA201001405 A EA 201001405A EA 201001405 A EA201001405 A EA 201001405A EA 201001405 A1 EA201001405 A1 EA 201001405A1
Authority
EA
Eurasian Patent Office
Prior art keywords
diabetes
derivatives
treatment
pyridopyrasinones
stimulators
Prior art date
Application number
EA201001405A
Other languages
English (en)
Other versions
EA020372B1 (ru
Inventor
Жерар Боттон
Эрик Валёр
Мишлине Кергоат
Кристине Шарон
Самер Эльбаваб
Original Assignee
Мерк Патент Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Патент Гмбх filed Critical Мерк Патент Гмбх
Publication of EA201001405A1 publication Critical patent/EA201001405A1/ru
Publication of EA020372B1 publication Critical patent/EA020372B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Настоящее изобретение относится к производным пиридопиразинона формулы (I), где X, Y, Z, W, А и R1 принимают значения, определенные в пункте 1, в качестве стимуляторов секреции инсулина. Изобретение также относится к получению и применению этих производных пиридопиразинона для профилактики и/или лечения диабета и связанных с ним патологий.
EA201001405A 2008-03-05 2009-02-27 Стимуляторы секреции инсулина - производные пиридопиразинонов, способы их получения и их применение для лечения диабета EA020372B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08004052 2008-03-05
PCT/EP2009/001428 WO2009109341A1 (en) 2008-03-05 2009-02-27 Pyridopyrazinones derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes

Publications (2)

Publication Number Publication Date
EA201001405A1 true EA201001405A1 (ru) 2011-04-29
EA020372B1 EA020372B1 (ru) 2014-10-30

Family

ID=40533371

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201001405A EA020372B1 (ru) 2008-03-05 2009-02-27 Стимуляторы секреции инсулина - производные пиридопиразинонов, способы их получения и их применение для лечения диабета

Country Status (18)

Country Link
US (3) US8178556B2 (ru)
EP (1) EP2247292B1 (ru)
JP (2) JP5735806B2 (ru)
KR (1) KR101589628B1 (ru)
CN (1) CN101951909B (ru)
AR (1) AR070796A1 (ru)
AU (1) AU2009221213B2 (ru)
BR (1) BRPI0908569B8 (ru)
CA (1) CA2718402C (ru)
DK (1) DK2247292T3 (ru)
EA (1) EA020372B1 (ru)
ES (1) ES2632964T3 (ru)
HU (1) HUE033849T2 (ru)
IL (1) IL207722A (ru)
MX (1) MX2010009577A (ru)
PT (1) PT2247292T (ru)
WO (1) WO2009109341A1 (ru)
ZA (1) ZA201007061B (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0008864A1 (en) 1978-08-15 1980-03-19 FISONS plc Pyridopyrazine and quinoxaline derivatives, processes for their preparation, and pharmaceutical compositions containing them
GB9413975D0 (en) 1994-07-11 1994-08-31 Fujisawa Pharmaceutical Co New heterobicyclic derivatives
JPH05155884A (ja) 1991-12-10 1993-06-22 Kyowa Hakko Kogyo Co Ltd 縮合ピラジン誘導体
GB9526558D0 (en) 1995-12-27 1996-02-28 Fujisawa Pharmaceutical Co Heterobicyclic derivatives
SE9800836D0 (sv) * 1998-03-13 1998-03-13 Astra Ab New Compounds
US6200976B1 (en) * 1998-04-17 2001-03-13 Boehringer Ingelheim Pharma Kg Antithrombotic quinoxazolines
DE19816983A1 (de) * 1998-04-17 1999-10-21 Boehringer Ingelheim Pharma Bicyclen, deren Herstellung und deren Verwendung als Arzneimittel
JP2000154139A (ja) * 1998-09-16 2000-06-06 Kyowa Hakko Kogyo Co Ltd 縮環ピラジン誘導体
WO2002076954A1 (en) * 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
US7067658B2 (en) 2002-09-30 2006-06-27 Bristol-Myers Squibb Company Pyridino and pyrimidino pyrazinones
WO2005021547A2 (en) * 2003-08-28 2005-03-10 Pharmaxis Pty Ltd. Heterocyclic cannabinoid cb2 receptor antagonists
ES2290782T3 (es) 2004-01-06 2008-02-16 Janssen Pharmaceutica N.V. Derivados de (3-oxo-3,4-dihidro-quinoxalin-2-il-amino)-benzamida y compuestos aferentes como inhibidores de la glucogeno fosforilasa en el tratamiento de la diabetes y de la obesidad.
CA2608672A1 (en) * 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3,4-b] pyrazinones as pde-5 inhibitors
WO2006126081A2 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridino [2 , 3-b] pyrazinones as pde-5 inhibitors
WO2006126083A1 (en) 2005-05-24 2006-11-30 Pharmacia & Upjohn Company Llc Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors
WO2007020521A1 (en) * 2005-08-16 2007-02-22 Pharmacia & Upjohn Company Llc Pyridoyrazinones as pde-5 inhibitors
EP2004193A2 (en) 2006-03-13 2008-12-24 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
WO2007109868A2 (en) * 2006-03-29 2007-10-04 Ivelin Terziev Fishing float
BRPI0710658A2 (pt) * 2006-04-21 2011-08-16 Pfizer Prod Inc compostos de piridina[3,4-b] pirazinonas, seus usos na preparação de composições farmacêuticas e composições farmacêuticas compreendendo os mesmos
CA2665476A1 (en) * 2006-10-05 2008-04-10 Cv Therapeutics, Inc. Bicyclic nitrogen-containing heterocyclic compounds for use as stearoyl coa desaturase inhibitors
US7893066B2 (en) 2006-10-05 2011-02-22 Gilead Palo Alto, Inc. Pyridol[2,3-B]pyrazinones for use as stearoyl CoA desaturase inhibitors
RU2488585C2 (ru) * 2007-08-31 2013-07-27 Пэдью Фарма Л.П. Замещенные пиперидиновые соединения хиноксалинового типа и их применение

Also Published As

Publication number Publication date
HUE033849T2 (en) 2018-01-29
JP6031079B2 (ja) 2016-11-24
JP2015034184A (ja) 2015-02-19
IL207722A (en) 2015-09-24
AR070796A1 (es) 2010-05-05
PT2247292T (pt) 2017-07-17
ES2632964T3 (es) 2017-09-18
JP5735806B2 (ja) 2015-06-17
EP2247292A1 (en) 2010-11-10
US20110009417A1 (en) 2011-01-13
CN101951909B (zh) 2013-05-15
WO2009109341A1 (en) 2009-09-11
KR20100124803A (ko) 2010-11-29
US8642617B2 (en) 2014-02-04
CA2718402C (en) 2017-08-22
MX2010009577A (es) 2010-09-24
AU2009221213A1 (en) 2009-09-11
EA020372B1 (ru) 2014-10-30
CA2718402A1 (en) 2009-09-11
BRPI0908569A2 (pt) 2015-09-22
IL207722A0 (en) 2010-12-30
BRPI0908569B1 (pt) 2020-02-11
US8178556B2 (en) 2012-05-15
US20130023537A1 (en) 2013-01-24
US8609689B2 (en) 2013-12-17
BRPI0908569B8 (pt) 2021-05-25
US20120122876A1 (en) 2012-05-17
CN101951909A (zh) 2011-01-19
AU2009221213B2 (en) 2014-02-27
KR101589628B1 (ko) 2016-01-28
ZA201007061B (en) 2011-06-29
EP2247292B1 (en) 2017-04-12
DK2247292T3 (en) 2017-06-06
JP2011514896A (ja) 2011-05-12

Similar Documents

Publication Publication Date Title
AU2016202535B2 (en) Fused heterocyclic compounds as sodium channel modulators
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
MA33939B1 (fr) 5-alcynyl-pyrimidines
MX2010009576A (es) Derivados de quinoxalinona como estimulantes de la secrecion de insulina, metodos para obtenerlos y su uso en el tratamiento de la diabetes.
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
MA32811B1 (fr) Nouveaux composés
EA201490493A1 (ru) Пирано[3,2-d][1,3]тиазол в качестве ингибиторов гликозидазы
EA201071144A1 (ru) Гетероциклические производные
DE602007008126D1 (de) Verfahren zur herstellung von (s)-4-fluormethyldihydrofuran-2-on
CL2011002604A1 (es) Compuestos derivados de n-(cianometil)-4-(sulfonil)pirrolidina-2-carboxamida, inhibidores de catepsina s o l; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o profilaxis de la diabetes, aterosclerosis, aneurismo aortico abdominal, enfermedades arteriales periferica o la nefropatia diabetica.
EA201001405A1 (ru) Стимуляторы секреции инсулина - производные пиридопиразинонов, способы их получения и их применение для лечения диабета
MY149648A (en) Carboxylalkylene-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
EA201101182A1 (ru) Новые аминоазагетероциклические карбоксамиды
EA201390579A1 (ru) Производные хиназолин-4(3h)-она, используемые как ингибиторы pi3-киназы
EA201270575A1 (ru) Соединения
EA201290416A1 (ru) Новые спиропиперидиновые соединения
MA32505B1 (fr) 5-alcynyl-pyrimidines
EA201201623A1 (ru) Лечение диабета 2 типа
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
EA201171339A1 (ru) Способ снижения внутриглазного давления у людей
EA201100254A1 (ru) Новые соединения
MX2014002112A (es) Compuestos de pirimido-piridazinona y uso de los mismos.
AU2011208681A8 (en) Aqueous solution comprising 3 - quinuclidinones for the treatment of hyperproliferative, autoimmune and heart disease
EA201001408A1 (ru) Производные пиразинона как стимуляторы секреции инсулина, способы их получения и их применение для лечения диабетов
IN2012DN00953A (ru)

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM